Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Dalton Signals Plan to Lift ASKA Stake to 30%; Board Weighs Countermeasures
ASKA Pharmaceutical Holdings said on August 18 that it has received a formal notice of intent from US investment fund Dalton Investments and two allied entities outlining plans to boost their stake to as much as 30% of the voting…
To read the full story
Related Article
- ASKA Shareholders Back Faster Poison Pill Activation
June 25, 2026
- ASKA Set to Seek Shareholder OK for Faster Poison Pill Activation
May 27, 2026
- ASKA Taps Ex-AbbVie Japan Chief Feliciano as Outside Director
May 12, 2026
- ASKA Keeps Defense Policy in Place as Dalton Dispute Persists
October 15, 2025
- Dalton Drops ASKA Stake Increase Plan, Slams Firm’s “Self-Preservation”
October 1, 2025
- ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
- ASKA Repeats Request to Dalton after Dismissive Email on Stake Plan
September 3, 2025
- ASKA Presses Dalton for Transparency on 30% Stake Plan
August 26, 2025
- ASKA Moves to Counter Dalton Investments’ Rapid Share Purchase
July 2, 2025
BUSINESS
- Medipal Names Imagawa as New CEO in 1st Leadership Change in 14 Years
September 9, 2026
- Kyowa Kirin’s nAMD Med Misses Mark in Global PII Study
September 9, 2026
- Belite Bio Files Stargardt Drug Tinlarebant in Japan
September 9, 2026
- AstraZeneca, Kyushu Electric Power Unit Pilot EV Charging Service
September 9, 2026
- Jardiance Takes Top Spot in Four Promotion Channels in July: Intage
September 9, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…